Tier 2 — strong

Comparison of shock wave therapy and nutraceutical composed of Echinacea angustifolia, alpha lipoic acid, conjugated linoleic acid and quercetin (perinerv) in patients with carpal tunnel syndrome

Angela Notarnicola, Giuseppe Maccagnano, Silvio Tafuri, Alessandra Fiore, Vito Pesce, Biagio Moretti
International journal of immunopathology and pharmacology 2015 28(2):256

Bibliography

PubMed
PMID 25953494
DOI
10.1177/0394632015584501
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized active-comparator clinical study
ModelHuman intervention research
Sample60 adults with carpal tunnel syndrome
InterventionMulti-ingredient nutraceutical including quercetin versus extracorporeal shock-wave therapy
DurationFollow-up through 6 months
EndpointsSymptoms and quality of life

What the study showed, in plain terms

Published in 2015, this source examined inflammation and clinical symptoms. Design: Randomized active-comparator clinical study. Sample/model: 60 adults with carpal tunnel syndrome. The exposure or intervention was Multi-ingredient nutraceutical including quercetin versus extracorporeal shock-wave therapy. Follow-up or treatment period: Follow-up through 6 months.

Both groups improved in symptoms and electrophysiology; a pain-regression trend favored the nutraceutical.

The formulation contained several active ingredients and no inert placebo. Quercetin-specific efficacy was not established.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Inflammation: CRP, Pain and Human Trials. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Both groups improved in symptoms and electrophysiology; a pain-regression trend favored the nutraceutical.
  • The recorded outcome domains were Symptoms and quality of life.
  • The result applies to the tested exposure: Multi-ingredient nutraceutical including quercetin versus extracorporeal shock-wave therapy; Follow-up through 6 months.

What this study can and cannot tell us

  • The formulation contained several active ingredients and no inert placebo. Quercetin-specific efficacy was not established.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
The Adjunctive Effect of Quercetin on Postoperative Pain Management Following Cesarean Section: A Randomized Controlled Study
Eman Mohamed Elmokadem et al. · Drug design, development and therapy · 2025
Tier 2
The effect of quercetin on iron overload and inflammation in β-thalassemia major patients: A double-blind randomized clinical trial
Zohreh Sajadi Hezaveh et al. · Complementary therapies in medicine · 2019
Tier 2
Flavonoid mixture (diosmin, troxerutin, rutin, hesperidin, quercetin) in the treatment of I-III degree hemorroidal disease: a double-blind multicenter prospective comparative study
Italo Corsale et al. · International journal of colorectal disease · 2018

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology